{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T22:09:23Z","timestamp":1768687763445,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["476624\/2011-8"],"award-info":[{"award-number":["476624\/2011-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoa de N\u00edvel Superior (CAPES)"},{"DOI":"10.13039\/501100006162","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Ci\u00eancia e Tecnologia do Estado de Pernambuco","doi-asserted-by":"crossref","award":["IBPG-1003-4.01\/12"],"award-info":[{"award-number":["IBPG-1003-4.01\/12"]}],"id":[{"id":"10.13039\/501100006162","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundo de Incentivo \u00e0 Pesquisa e Evento do Hospital de Cl\u00ednicas de Porto Alegre (FIPE\/HCPA)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bcmd.2016.10.016","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T15:01:47Z","timestamp":1477321307000},"page":"200-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Could enzyme replacement therapy promote immune tolerance in Gaucher disease type 1?"],"prefix":"10.1016","volume":"68","author":[{"given":"Marina Cadena","family":"Matta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Vairo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leuridan Cavalcante","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3517-6615","authenticated-orcid":false,"given":"Ida","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9645","key":"10.1016\/j.bcmd.2016.10.016_bb0005","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher's disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2016.10.016_bb0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/asheducation.V2012.1.13.3797921","article-title":"Gaucher disease and other storage disorders","volume":"2012","author":"Grabowski","year":"2012","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"3","key":"10.1016\/j.bcmd.2016.10.016_bb0015","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1479-7364-5-3-156","article-title":"Lysosomal storage disorders: molecular basis and laboratory testing","volume":"5","author":"Filocamo","year":"2011","journal-title":"Hum. Genomics"},{"issue":"6","key":"10.1016\/j.bcmd.2016.10.016_bb0020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpedi.160.6.603","article-title":"The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis","volume":"160","author":"Kaplan","year":"2006","journal-title":"Arch. Pediatr. Adolesc. Med."},{"issue":"1","key":"10.1016\/j.bcmd.2016.10.016_bb0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2014.02.005","article-title":"Gaucher disease","volume":"4","author":"Nagral","year":"2014","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"1\u20132","key":"10.1016\/j.bcmd.2016.10.016_bb0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \u201csimple disorder\u201d","volume":"83","author":"Sidransky","year":"2004","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.bcmd.2016.10.016_bb0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00401-007-0296-4","article-title":"Immune system irregularities in lysosomal storage disorders","volume":"115","author":"Castaneda","year":"2008","journal-title":"Acta. Neuropathol."},{"key":"10.1016\/j.bcmd.2016.10.016_bb0040","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.2147\/DDDT.S77760","article-title":"Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease","volume":"9","author":"Bennett","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcmd.2016.10.016_bb0045","article-title":"Enzyme replacement and substrate reduction therapy for Gaucher disease","volume":"3","author":"Shemesh","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.bcmd.2016.10.016_bb0050","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol. Med."},{"issue":"3","key":"10.1016\/j.bcmd.2016.10.016_bb0055","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","article-title":"Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis","volume":"108","author":"de Fost","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bcmd.2016.10.016_bb0060","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/stem.1732","article-title":"Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development","volume":"32","author":"Panicker","year":"2014","journal-title":"Stem Cells"},{"issue":"6","key":"10.1016\/j.bcmd.2016.10.016_bb0065","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","article-title":"Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration","volume":"93","author":"Rosenberg","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcmd.2016.10.016_bb0070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jaci.2012.10.058","article-title":"Can we produce true tolerance in patients with food allergy?","volume":"131","author":"Berin","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.bcmd.2016.10.016_bb0075","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.4049\/jimmunol.168.7.3195","article-title":"Luster AD.IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking","volume":"168","author":"Dufour","year":"2002","journal-title":"J. Immunol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616302157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616302157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:33:17Z","timestamp":1761049997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616302157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":15,"alternative-id":["S1079979616302157"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.016","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Could enzyme replacement therapy promote immune tolerance in Gaucher disease type 1?","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}